

# Charbonneau News

## Meeting the Cancer Challenge

### Director's Message

Dear Friends,

I hope you all had a great summer! Since our last newsletter, there have been some major accomplishments by our Institute's members and trainees. In this edition, you'll read about some of these successes, including publications in high impact journals and new funding.

Our trainees have been busy planning our second public lecture, "Cancer in Young People", which was held on October 4 at Studio Bell. It was another great event and we are looking forward to the next one.

I wish you all an enjoyable fall.

Greg

### Contact Us

Arnie Charbonneau Cancer Institute  
3280 Hospital Drive NW  
Calgary, AB  
Phone: (403) 210-3934  
Email: [charbonneau@ucalgary.ca](mailto:charbonneau@ucalgary.ca)  
Website: [charbonneau.ucalgary.ca](http://charbonneau.ucalgary.ca)

"Follow us" and "Like us"



### this issue

Announcements P.1

Education & Training P.4

Facilities P.6

Research & Features P.7

Quarterly Bibliography P.10

## Announcements

### Late Night Lab at Studio Bell: Cancer in Young People

The Charbonneau Trainee Association hosted another successful public lecture on October 4<sup>th</sup>, 2019 at Studio Bell, featuring talks by several Institute members, including Drs. Jennifer Chan, Miranda Fidler-Benaoudia, Michael Monument, and Fiona Schulte (pictured below).

The talks began with an introduction by Dr. Jennifer Chan on the differences between cancer in young people and cancer in older people, followed by an overview by Dr. Miranda Fidler-Benaoudia of cancer incidence and trends in young people and some of the survivorship issues facing young survivors. The talk then focused on sarcoma, as a type of malignancy that often impacts young people, and Dr. Michael Monument shared examples of how this tumour is treated and where the future of treatment for sarcoma is headed. Finally, the lecture wrapped up with an overview by Dr. Fiona Schulte on the psychosocial issues facing young people with cancer and their families.

The next public lecture will be held on June 3<sup>rd</sup>, 2020 at Calgary Central Library.



## Welcome New Members



Dr. Harry Peery  
Cell Biology & Anatomy

Area of Focus: Imaging tumors with a cell mass of less than a million cells



Dr. Natalie Logie  
Radiation Oncology

Area of Focus: Outcomes for pediatric patients receiving radiotherapy and correlations with dosimetry



Dr. Doreen Ezeife  
Medical Oncology

Area of Focus: Health services research, cancer drug access

## Congratulations to Strategic Advisory Board Member, Keith MacPhail, on being named to the Order of Canada

Strategic Advisory Board Member, Keith MacPhail was announced as a Member of the Order of Canada in recognition of his "achievements as a business leader and philanthropic contributions to health, education, and sport initiatives". Mr. MacPhail gave generously to the Forzani-MacPhail Colorectal Cancer Screening Centre.



## Congratulations to Dr. Christine Friedenreich on being named a Royal Society of Canada Fellow

Dr. Christine Friedenreich, Adjunct Professor in the Departments of Oncology and Community Health Sciences and Scientific Director of the Department of Cancer Epidemiology and Prevention at CancerControl Alberta, was recently named a Royal Society of Canada Fellow. This prestigious award recognizes individuals who have made remarkable contributions in the arts, humanities, and sciences, as well as in Canadian public life.



## Congratulations to Dr. Nicole Culos-Reed on her Research Excellence Award, from CIHR—Institute of Cancer Research

Dr. Nicole Culos-Reed, Professor in the Faculty of Kinesiology, was recognized with a Research Excellence Award through the Canadian Association of Psychosocial Oncology (CAPO) for her significant career contributions in psychosocial oncological research and practice. She co-leads the Alberta Cancer Exercise (ACE) program, a free community-based, 12-week exercise program for survivors of cancer to improve their recovery.



## Congratulations to Dr. Kristina Rinker on receiving an Innovation Fellowship from Parex Resources

Dr. Kristina Rinker, Associate Professor in the Schulich School of Engineering, was one of six scientists included in the 2019-2020 cohort of Innovation Fellowship recipients.



## Welcome New Members



Dr. Safiya Karim  
Medical Oncology

Area of Focus: Health Services  
Research and Quality  
Improvement



Dr. Lorraine Shack  
Oncology

Area of Focus: Outcomes,  
Surveillance, Epidemiology



Dr. Colleen Cuthbert  
Faculty of Nursing

Area of Focus: Cancer  
Survivorship

## New Faculty Orientation and Introduction to research at CSM!

Charbonneau participated in the first ever Cumming School of Medicine Open House.



## CELEBRATE THE SEASON



Charbonneau families are invited to attend our annual Kids Holiday Party at no cost.

A wrapped and tagged gift (\$25) must be dropped off to the Admin Office in HRIC 2AA-07 by Friday December 13<sup>th</sup>.

RSVP by December 9<sup>th</sup>.



Charbonneau full members, trainees, lab staff and administrative staff all invited at no cost.

A spousal ticket can be purchased for \$85.00

Tickets will be available for pick up in HRIC 2AA-07 starting November 5<sup>th</sup>.



## Education & Training

### TRAINEE SUCCESS

#### Postdoctoral Fellowship Awards

**Dr. Seungil Paik**, Supervised by Dr. Marco Gallo  
**Dr. Dylan O'Sullivan**, Supervised by Dr. Darren Brenner  
**Dr. Noemi Leblay**, Supervised by Dr. Paola Neri  
**Dr. Sacha Benaoudia**, Supervised by Dr. Doug Mahoney

#### Clark Smith Brain Tumour Centre Graduate Studentships

**Aly Abdelkareem**, Supervised by Dr. Sorana Morrissy  
**Rujuta Deshpande**, Supervised by Dr. Savraj Grewal  
**Alisha Poole**, Supervised by Dr. Steve Robbins

#### ACF Fred Coles Cancer Research Post-Doctoral Fellowship

**Sarah Moradi-Fard**, Supervised by Dr. Gareth Williams

#### Kids Brain Cancer Canada Research Award

**Francesca Maule**, Supervised by Dr. Marco Gallo

Congratulations to the following Charbonneau trainees who were awarded travel awards to attend the Canadian Cancer Research Conference in Ottawa, November 3-5, 2019.

|                      |                           |
|----------------------|---------------------------|
| <b>Kayla Marritt</b> | <b>Liane Babes</b>        |
| <b>Daniel Meyers</b> | <b>Victoria Armstrong</b> |
| <b>Hend Zaaluk</b>   | <b>Dustin Pearson</b>     |
| <b>Jannat Pervin</b> | <b>Jodi Rattner</b>       |
| <b>Lisa Liang</b>    | <b>Mariel Kleer</b>       |

**Yang Yang**, Supervised by Drs. Karl Riabowol & Shirin Bonni successfully defended her PhD thesis

**Hend Zaluk**, Supervised by Dr. Tarek Bismar successfully defended her MSc thesis

### Upcoming Event

#### SAVE THE DATE

5<sup>TH</sup> Annual Cancer Research Symposium

February 10, 2020

#### Keynote Speaker:

**Dr. Michael Chu**, University of Alberta

### Upcoming Distinguished Speaker Series

November 15, 2019  
**Dr. Daniel Schramek**  
Lunenfeld-Tanenbaum Research Institute

December 6, 2019  
**Dr. Guy Poirier**  
Université Laval

January 24, 2020  
**Dr. Julie St. Pierre**  
University of Ottawa

### Faculty Lunch Chalk Talks

11:00-12:00pm  
(Fridays)

Applying for an upcoming grant? Want to present your idea at a Faculty Lunch Talk?

Secure your date!  
Contact Carmen  
ccoelho@ucalgary.ca

## UPCOMING FUNDING OPPORTUNITIES

### Charbonneau Scholarship Award Opportunities


- Charbonneau Institute Director Graduate Scholarship in Cancer Research
- Daniel Family Foundation Graduate Scholarship in Cancer Research

### Howard Research Excellence Awards

- Open to both graduate students and postdoctoral fellows

*Full details on how to apply will be communicated soon*

# Charbonneau Trainee Association



## CTA Highlights

Summer Student Research Day

Summer BBQ at Edworthy Park

New Student Orientation

WIP Workshop

Trainee Townhall

## Trainee Survey Results

Thank you to all trainees who participated in the Trainee Survey. Survey results indicated that about 75% of our trainees were satisfied with their experience in the Charbonneau and felt that it is a beneficial community. In regards to Work-in-Progress (WIP) and Journal Club, about 50% of trainees were happy with the current format of these requirements. Using the data from this survey, we hope to make changes to improve the engagement of trainees and the overall satisfaction with WIP and Journal Club. The CTA is making a conscious effort to include your opinions and feedback to help inform the changes we make. If you have any suggestions or comments, please do not hesitate to contact the CTA.

## Professional Development Workshops

One of the main things trainees wanted more of was the offering of professional development workshops. We have worked closely with campus resources to design and implement a series of workshops for all trainees. The first workshop will take place November 22, 2019. Details to come.

## Upcoming Events:

Halloween Party

Oct 31, 2019

HRIC Hallway

PD Workshop

Nov 22, 2019

11:30 – 1:00

Details about all upcoming events will be sent out via the CTA email.

If you have any questions or comments, please email us at:

[charbonneau.trainee.association@gmail.com](mailto:charbonneau.trainee.association@gmail.com)

Follow us on instagram:

@Charbonneau\_Cancer\_Institute

## Save the Date: 6<sup>th</sup> Annual Cancer Research Symposium



Keynote Speaker: Dr. Micheal Chiu,  
University of Alberta

Date: February 10<sup>th</sup>, 2020

Location: Theatre 4

Abstract and Registration Deadline:  
January 29<sup>th</sup>, 2020

All Charbonneau graduate students and postdoctoral fellows are encouraged to present a poster. E-mail with details and information to come



## Safety Reminders

Emergency eyewash stations need to be activated weekly for at least one minute to verify operation and flush any sediment and potential contaminate. There was an incident on main campus where an eye wash station did not work when required. King Hsieh will perform this weekly check to ensure it is being consistently done within the Institute.

### Did you know?

Emergency response and business continuity planning is the process to ensure the appropriate process continuation and recovery of business functions in the event that an incident disrupts University of Calgary's ability to operate. Floods, fires, power outages, blizzards, major computer system outages and water main breaks are examples of unanticipated events that can have a devastating impact on the University unless preparation has taken place. The Charbonneau Lab Manager's group will be developing a Charbonneau Business Continuity Plan over the next year. Our first order of business will be to develop a plan for an extended power outage.

## Facilities & Infrastructure



**Donna Wray recognized with a Shining Star Award for her commitment to safety on campus!**

Donna was recognized for her proactive approach to lab safety issues including Fixed Gas Detection, inspections, equipment maintenance, training and development of safety protocols/procedures.



**PRECISION**  
ONCOLOGY HUB

by Dr. Paola Neri

The Precision Oncology Hub is a translational laboratory located in the Tom Baker Cancer Center established to support the translation of research discovery into improved care. By incorporating molecular profiling through biomarker discovery and genomic sequencing studies into cancer management and treatment approaches, we aim to become the Hub for clinical and translational research and provide a better understanding of cancer biology and ultimately deliver personalized therapy to patients.

Several cancers are characterized by a complex molecular pathogenesis and intra- and inter-tumor heterogeneity. Therefore biomarker discovery and genomic studies are extremely important for understanding disease biology in individual patients, the identification of druggable targets, and the delivery of a personalized therapeutics. Furthermore, in the field of immunotherapy, we intend to develop methods to better understand mechanisms deregulating the immune fitness of cancer patients. Those approaches will help to enhance our understanding of the mechanisms mediating the immune tolerance in cancer patients, and identify and validate diagnostic markers (predictive and/or prognostic) of the patient's immune "health" status with the aim to implement novel ways to reverse immune tolerance.

We are a team of experts in proteomics, genomics, immunology, and computational biology with the goal to identify the molecular changes that drive cancer progression, discover new targets for therapy, and select drugs based on the "multi-omics" profile of the tumor. Those approaches are critical to guide selection of combination therapies for cancer patients, minimize the use of potentially ineffective therapeutics, and hence lessen any potentially harmful side effects of administered therapeutics. The Precision Oncology Hub has ongoing collaborations with different tumor group leaders in the Department of Oncology and with members of the Arnie Charbonneau Cancer Institute. We also foster collaborations with other oncology programs and industry partners to speed the translation of research discovery into improved patient care and lead to personalized medicine for each cancer patient.



## Upcoming Major External Grants:

### NSERC Discovery Grant:

Application deadline:  
November 1, 2019

### Movember Translation Acceleration Grant:

Application deadline:  
November 12, 2019

### New Frontiers in Research Fund – Exploration 2019:

Application deadline:  
December 10, 2019

### Leukemia and Lymphoma Society of Canada Operating:

LOI deadline: October 25, 2019

Application deadline:  
February 5, 2020

### CIHR Team Grant : Personalized Health:

LOI deadline: October 8, 2019

Application deadline:  
April 7, 2020

**NOTE:** Plan ahead! The RSO deadline is two days earlier!

## Reminder: Internal Peer Review

Do you plan to submit a grant to CRS? CIHR? CCSRI?

If yes, have you registered for internal peer review?

To schedule a 'Chalk Talk' lunch or peer review meeting, or 1:1 feedback, contact:

**Savraj Grewal**  
[grewalss@ucalgary.ca](mailto:grewalss@ucalgary.ca)

or **Melissa Shea-Budgell**  
[melissa.sheabudgell@ucalgary.ca](mailto:melissa.sheabudgell@ucalgary.ca)

## News to Share?

Have you received a new grant or award? Has your student recently defended?

Please share your story with us! We are looking for content for LinkedIn, the website, and the newsletter!

# Research News

## Congratulations to the Following Grant and Award Recipients, Q2 2019-20:




Canadian Institutes of Health Research (CIHR)


Five Charbonneau members receive new Project Grants from CIHR



Jason Tay  
MD



Jennifer Chan  
MD



Douglas Mahoney  
PhD



Darren Brenner  
PhD



Robert Hilsden  
MD



Canadian Cancer Society  
Société canadienne du cancer

### *Innovation Grants – Prevention and Quality of Life*

Lauren Walker, PhD




### *TENET i2c competition*

Oliver Bathe, MD



### *International Psychosocial Oncology Society Bernard Fox Memorial Award*

Linda Carlson, PhD



### *Department of Oncology Research Office Seed Grant*

Safiya Karim, MD

# Feature Articles

2019 June 25 – 2019 September 24

## Feature Article:

Gene responsible for repressing the immune response, maintains stem-cell-like properties in GBM.



### Marco Gallo, PhD

Brain Cancer Epigenomics  
Clark Smith Brain Tumor Centre  
Physiology & Pharmacology

**Trainees:** Johnston MJ, Nikolic A

*Genome Research* 2019

Glioblastoma multiforme (GBM) is the most common type of malignant brain tumour in adults. Relapse is common and current treatment approaches have been largely ineffective at curing the disease. Dr. Gallo's work showed that CD276, a gene responsible for repressing the immune response, maintains stem-cell-like properties in GBM stem cells. According to Dr. Gallo, targeting CD276 with immunotherapy could be an effective way to kill cancer stem cells and prevent relapse of GBM.

## Feature Article:

Cancer cells can adapt to low oxygen conditions by modulating lipid metabolism.



### Jennifer Cobb, PhD

Genome Instability  
Robson DNA Science Centre  
Biochemistry & Molecular Biology

**Trainee:** Mojumdar A

*Cell Reports* 2019; 28(6):1564-1573.e3.

Repair of DNA damage, due to normal metabolic activities and environmental factors, occurs in the body on a regular basis. However, double strand breaks (damage to both strands of the DNA double helix) can pose problems for transcription and replication, resulting in genome instability. Dr. Cobb and her team provide insight on how double strand breaks may be stabilized, the role of specific repair factors in tethering broken DNA ends, and chromosome deletions associated with defects in tethering broken DNA ends.

## Feature Article:

Targeting dipeptidase-1 can reduce neutrophil recruitment to the lungs and liver.



### Donna Senger, PhD Steve Robbins, PhD

Clark Smith Brain Tumor Centre  
Oncology

**Trainees:** Choudhury SR, Babes L

*Cell* 2019; 178(5):1205-21.e17

Recruitment of neutrophils to the lungs during an infection can lead to death. However, it was unknown what causes these cells to migrate to the lungs and accumulate there. Moreover, an understanding of this mechanism may inform how cancer metastasizes to the lungs. Drs. Senger and Robbins, with other Charbonneau scientists, discovered that dipeptidase 1 is a vascular adhesion molecule in lungs and liver and that targeting dipeptidase 1 reduces death from sepsis in mice.



# Feature Articles

2019 June 25 – 2019 September 24

## Feature Article:

Anti-adhesion glycoprotein (rhPRG4) suppresses growth of breast tumour cells.



### Shirin Bonni, PhD

Cancer Biology  
Homeostasis and cancer  
Biochemistry & Molecular Biology

**Trainees:** Sarkar A, Chanda A, Karve K

*PLoS One* 2019; 14(7):e0219697

Metastasis of the primary tumour is a major cause of cancer morbidity and mortality. Once breast cancer has metastasized, it is incurable and treatment focuses on controlling the disease. Dr. Shirin Bonni and her team studied the role of recombinant human PRG4 (rhPRG4) in reducing the invasiveness of breast cancer cells. She found that rhPRG4 opposes HAS2 and CD44 induction by TGF $\beta$ , and may have clinical utility as a potential treatment for invasive and metastatic breast cancer.

## Feature Article:

Aggressive end-of-life measures in the last 30 days of life less common in Alberta



### Winson Cheung, MD, MPH

Real World Evidence | Alberta  
Cancer Outcomes Research Network  
Oncology

**Trainee:** Cuthbert C

*ASCO Post* 2019 September 3

Aggressive care at end of life can lead to unnecessary invasive interventions for patients, distress for care takers, and strain on an already burdened health system. Aggressive treatment within the last 30 days of life is not recommended. Dr. Winson Cheung and his team, in collaboration with researchers in Washington state, found that chemotherapy use in the last 30 days of life and ICU admissions were lower in Alberta than in Washington. An understanding of the drivers of inappropriate care is needed.

## Feature Article:

Individuals with inherited defects in natural killer cells have a higher risk of developing cancer.



### Edwin Wang, PhD

Bioinformatics | Precision Medicine  
Cancer Genomics and Informatics  
Biochemistry and Molecular Biology

**Trainees:** Xu X, Zou J, Feng X

*JAMA Network Open* 2019; 2(9):e199292

Dr. Edwin Wang and his team studied the impact of inherited defects in natural killer cell genes on cancer risk. They found that inherited defects are associated with tumour immune microenvironment subtypes, recruitment of tumour infiltrating lymphocytes, response to immune checkpoint therapy, and clinical outcomes. The findings of this work have implications for both detecting cancers with germline variants of natural killer cells and improving immune checkpoint therapies.

# Quarterly Cancer Bibliography

2019 June 25 – 2019 September 24

## Population Health (Prevention and Early Detection) Research

1. **Brenner DR**. Using Machine Learning to Bend the Cost Curve-Addressing High-Cost Targeted Therapeutics. *JAMA Netw Open*. 2019 Sep 4;2(9):e1911913. doi: 10.1001/jamanetworkopen.2019.11913. PubMed PMID: 31553464.
2. Sripan P, Chitapanarux I, **Fidler-Benaoudia MM**, Miranda-Filho A, Bardot A, Pongnikorn D, Maneesai P, Waisri N, Hanpragopsuk C, Tharavichitkul E, Soerjomataram I. Impact of universal health care and screening on incidence and survival of Thai women with cervical cancer: A population-based study of the Chiang Mai Province. *Cancer Epidemiol*. 2019 Sep 17;63:101594. doi: 10.1016/j.canep.2019.101594. PubMed PMID: 31539716.
3. Haider S, Grabovac I, Smith L, Stefanac S, Jackson SE, Li Y, Cao C, Waldhoer T, Zhang Y, Dorner TE, **Yang L**. Health Care Providers' Advice on Lifestyle Modification for Older Adults. *J Am Med Dir Assoc*. 2019 Sep 16. pii: S1525-8610(19)30579-1. doi: 10.1016/j.jamda.2019.07.019. [Epub ahead of print] PubMed PMID: 31537481.
4. Viner B, Barberio AM, Haig TR, **Friedenreich CM**, **Brenner DR**. The individual and combined effects of alcohol consumption and cigarette smoking on site-specific cancer risk in a prospective cohort of 26,607 adults: results from Alberta's Tomorrow Project. *Cancer Causes Control*. 2019 Sep 18. doi: 10.1007/s10552-019-01226-7. [Epub ahead of print] PubMed PMID: 31535325.
5. McNeely ML, Sellar C, Williamson T, **Shea-Budgell M**, Joy AA, Lau HY, Easaw JC, Murtha AD, Vallance J, Courneya K, Mackey JR, Parliament M, **Culos-Reed N**. Community-based exercise for health promotion and secondary cancer prevention in Canada: protocol for a hybrid effectiveness-implementation study. *BMJ Open*. 2019 Sep 13;9(9):e029975. doi: 10.1136/bmjopen-2019-029975. PubMed PMID: 31519676.
6. Rydz E, Arrandale VH, **Peters CE**. Population-level estimates of workplace exposure to secondhand smoke in Canada. *Can J Public Health*. 2019 Sep 5. doi: 10.17269/s41997-019-00252-x. [Epub ahead of print] PubMed PMID: 31489599.
7. Smith L, Jackson SE, Jacob L, Grabovac I, Nisbet LA, López-Sánchez GF, McDermott D, Salmeron AG, **Yang L**, Koyanagi A. Association between cannabis use and sexual behavior among adolescents aged 12-15 years in 21 low- and middle-income countries. *Addict Behav*. 2019 Aug 1;99:106073. doi: 10.1016/j.addbeh.2019.106073. PubMed PMID: 31421584.
8. Sweegers MG, Boyle T, **Vallance JK**, Chinapaw MJ, Brug J, Aaronson NK, D'Silva A, Kampshoff CS, Lynch BM, Nollet F, Phillips SM, Stuiver MM, van Waart H, Wang X, Buffart LM, Altenburg TM. Which cancer survivors are at risk for a physically inactive and sedentary lifestyle? Results from pooled accelerometer data of 1447 cancer survivors. *Int J Behav Nutr Phys Act*. 2019 Aug 16;16(1):66. doi: 10.1186/s12966-019-0820-7. PubMed PMID: 31420000; PubMed Central PMCID: PMC6698042.
9. **Peters CE**, Bogaert L, Latifovic L, Kachuri L, Harris SA, Parent ME, Villeneuve PJ; Canadian Cancer Registries Epidemiology Group. Exposure to crystalline silica in Canadian workplaces and the risk of kidney cancer. *Occup Environ Med*. 2019 Sep;76(9):668-671. doi: 10.1136/oemed-2019-105870. PubMed PMID: 31413189.



## **Population Health (Prevention and Early Detection) Research (continued)**

10. Grad R, Thériault G, Singh H, **Dickinson JA**, Szafran O, Bell NR. Age to stop? Appropriate screening in older patients. *Can Fam Physician*. 2019 Aug;65(8):543-548. PubMed PMID: 31413022; PubMed Central PMCID: PMC6693611.
11. Grabovac I, Veronese N, Stefanac S, Haider S, Jackson SE, Koyanagi A, Meilinger M, Stubbs B, Firth J, Soysal P, Di Gennaro F, Demurtas J, McDermott DT, Abbs AD, **Yang L**, Smith L. Human Immunodeficiency Virus Infection and Diverse Physical Health Outcomes: An Umbrella Review of Meta-analyses of Observational Studies. *Clin Infect Dis*. 2019 Aug 11. pii: ciz539. doi: 10.1093/cid/ciz539. [Epub ahead of print] PubMed PMID: 31401650.
12. **Friedenreich CM**, Wang Q, Shaw E, Heer EV, Zhou R, **Brenner DR**, Courneya KS, Wynne-Edwards KE. The effect of prescribed exercise volume on biomarkers of chronic stress in postmenopausal women: Results from the Breast Cancer and Exercise Trial in Alberta (BETA). *Prev Med Rep*. 2019 Jul 22;15:100960. doi: 10.1016/j.pmedr.2019.100960. eCollection 2019 Sep. PubMed PMID: 31384527; PubMed Central PMCID: PMC6664156.
13. **Friedenreich CM**, Wang Q, Yasui Y, Stanczyk FZ, Duha A, **Brenner DR**, Courneya KS. Long-term Effects of Moderate versus High Durations of Aerobic Exercise on Biomarkers of Breast Cancer Risk: Follow-up to a Randomized Controlled Trial. *Cancer Epidemiol Biomarkers Prev*. 2019 Aug 5. doi: 10.1158/1055-9965.EPI-19-0523. PMID: 31383718.
14. **Brenner DR**, Heer E, Sutherland RL, Ruan Y, Tinmouth J, Heitman SJ, **Hilsden RJ**. National Trends in Colorectal Cancer Incidence Among Older and Younger Adults in Canada. *JAMA Netw Open*. 2019 Jul 3;2(7):e198090. doi: 10.1001/jamanetworkopen.2019.8090. PubMed PMID: 31365108; PubMed Central PMCID: PMC6669779.
15. Jackson SE, Smith L, Firth J, Grabovac I, Soysal P, Koyanagi A, Hu L, Stubbs B, Demurtas J, Veronese N, Zhu X, **Yang L**. Is there a relationship between chocolate consumption and symptoms of depression? A cross-sectional survey of 13,626 US adults. *Depress Anxiety*. 2019 Jul 29. doi: 10.1002/da.22950. [Epub ahead of print] PubMed PMID: 31356717.
16. Smith L, Jackson SE, Jacob L, Grabovac I, **Yang L**, Johnstone J, McDermott D, Gordon D, Lopez Sanchez GF, Stefanac S, Koyanagi A. Leisure-Time Sedentary Behavior, Alcohol Consumption, and Sexual Intercourse Among Adolescents Aged 12-15 Years in 19 Countries From Africa, the Americas, and Asia. *J Sex Med*. 2019 Sep;16(9):1355-1363. doi: 10.1016/j.jsxm.2019.06.013. Epub 2019 Jul 24. PubMed PMID: 31351852.
17. Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, **Yang L**, Glybochko PV, Rink M, Abufaraj M. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. *World J Urol*. 2019 Jul 18. doi: 10.1007/s00345-019-02875-8. [Epub ahead of print] PubMed PMID: 31321509.
18. McNeil J, Liepert M, **Brenner DR**, Courneya KS, **Friedenreich CM**. Behavioral Predictors of Weight Regain in Postmenopausal Women: Exploratory Results From the Breast Cancer and Exercise Trial in Alberta. *Obesity (Silver Spring)*. 2019 Sep;27(9):1451-1463. doi: 10.1002/oby.22569. Epub 2019 Jul 18. PubMed PMID: 31318492.
19. Jackson SE, Firth J, Grabovac I, Koyanagi A, Stubbs B, Soysal P, Willmott A, **Yang L**, Smith L. Sedentary behaviour and chronic stress in old age: A cross-sectional analysis of TV viewing and hair cortisol concentrations. *Psychoneuroendocrinology*. 2019 Jul 5;109:104375. doi: 10.1016/j.psyneuen.2019.104375. [Epub ahead of print] PubMed PMID: 31302361.

### **Population Health (Prevention and Early Detection) Research (continued)**

20. **McDonough MH**, Beselt LJ, Daun JT, Shank J, **Culos-Reed SN**, Kronlund LJ, Bridel W. The role of social support in physical activity for cancer survivors: A systematic review. *Psychooncology*. 2019 Jul 6. doi: 10.1002/pon.5171. Review. PubMed PMID: 31278800.
21. **Peters CE**, Kim J, Song C, Heer E, Arrandale VH, Pahwa M, Labrèche F, McLeod CB, Davies HW, Ge CB, Demers PA. Burden of non-melanoma skin cancer attributable to occupational sun exposure in Canada. *Int Arch Occup Environ Health*. 2019 Jul 3. doi: 10.1007/s00420-019-01454-z. [Epub ahead of print] PubMed PMID: 31270593.
22. Allodji RS, Hawkins MM, Bright CJ, **Fidler-Benaoudia MM**, Winter DL, Alessi D, ... Michel G, Kremer LCM, Hjorth L, Haddy N, de Vathaire F, Reulen RC. Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. *Eur J Cancer*. 2019 Aug;117:71-83. doi: 10.1016/j.ejca.2019.05.013. PubMed PMID: 31260818.
23. O'Sullivan DE, **Brenner DR**, Villeneuve PJ, Walter SD, Demers PA, **Friedenreich CM**, King WD; ComPARE Study Team. Corrigendum to "Estimates of the current and future burden of melanoma attributable to ultraviolet radiation in Canada" [*Prev. Med.* 122 (2019) 81-90]. *Prev Med*. 2019 Sep;126:105728. doi: 10.1016/j.ypmed.2019.05.016. Epub 2019 Jun 18. PubMed PMID: 31227246.
24. Smith L, Firth J, Grabovac I, Koyanagi A, Veronese N, Stubbs B, Soysal P, **Yang L**, Jackson SE. The association of grip strength with depressive symptoms and cortisol in hair: A cross-sectional study of older adults. *Scand J Med Sci Sports*. 2019 Oct;29(10):1604-1609. doi: 10.1111/sms.13497. Epub 2019 Jun 27. PubMed PMID: 31206201.
25. Pahwa M, Labrèche F, Kim J, Harris MA, Song C, **Peters CE**, Arrandale VH, Davies H, McLeod CB, Demers PA. The impact of night shift work on breast cancer: Results from the Burden of Occupational Cancer in Canada Study. *Am J Ind Med*. 2019 Aug;62(8):635-642. doi: 10.1002/ajim.22999. Epub 2019 Jun 6. PubMed PMID: 31172551.
26. **Peters CE**, Pasko E, Strahlendorf P, Holness DL, Tenkate T. Solar Ultraviolet Radiation Exposure among Outdoor Workers in Three Canadian Provinces. *Ann Work Expo Health*. 2019 Jul 24;63(6):679-688. doi: 10.1093/annweh/wxz044. PubMed PMID: 31165866.
27. Ertl R, Waldhoer T, **Yang L**. Moderate altitude impacts birth weight: 30 years retrospective sibling analyses using record linkage data. *Pediatr Res*. 2019 Sep;86(3):403-407. doi: 10.1038/s41390-019-0434-4. PubMed PMID: 31112991.
28. **Tremblay A**, Taghizadeh N, Huang J, Kasowski D, MacEachern P, Burrowes P, Graham AJ, **Dickinson JA**, Lam SC, Yang H, Koetzler R, Tammemagi M, Taylor K, Bédard ELR. A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program. *J Thorac Oncol*. 2019 Sep;14(9):1528-1537. doi: 10.1016/j.jtho.2019.04.024. PubMed PMID: 31077790.
29. Gonzalo-Encabo P, McNeil J, Boyne DJ, Courneya KS, **Friedenreich CM**. Dose-response effects of exercise on bone mineral density and content in post-menopausal women. *Scand J Med Sci Sports*. 2019;29(8):1121-9. doi: 10.1111/sms.13443. PMID: 31034640.
30. **Hilsden RJ**, Rose SM, Dube C, Rostom A, Bridges R, McGregor SE, **Brenner DR**, Heitman SJ. Defining and Applying Locally Relevant Benchmarks for the Adenoma Detection Rate. *Am J Gastroenterol*. 2019;114(8):1315-21. doi: 10.14309/ajg.000000000000120. PubMed PMID: 30848731.

### **Population Health (Prevention and Early Detection) Research (continued)**

31. Lynch BM, Nguyen NH, Moore MM, Reeves MM, Rosenberg DE, Boyle T, **Vallance JK**, Milton S, **Friedenreich CM**, English DR. A randomized controlled trial of a wearable technology-based intervention for increasing moderate to vigorous physical activity and reducing sedentary behavior in breast cancer survivors: The ACTIVATE Trial. *Cancer*. 2019 Aug 15;125(16):2846-2855. doi: 10.1002/cncr.32143. Epub 2019 Apr 23. PubMed PMID: 31012970.
32. Lynch BM, Nguyen NH, Moore MM, Reeves MM, Rosenberg DE, Boyle T, Milton S, **Friedenreich CM**, **Vallance JK**, English DR. Maintenance of physical activity and sedentary behavior change, and physical activity and sedentary behavior change after an abridged intervention: Secondary outcomes from the ACTIVATE Trial. *Cancer*. 2019 Aug 15;125(16):2856-2860. doi: 10.1002/cncr.32142. Epub 2019 Apr 23. PubMed PMID: 31012968.
33. Grabovac I, Smith L, McDermott DT, Stefanac S, **Yang L**, Veronese N, Jackson SE. Well-Being Among Older Gay and Bisexual Men and Women in England: A Cross-sectional Population Study. *J Am Med Dir Assoc*. 2019 Sep;20(9):1080-1085.e1. doi: 10.1016/j.jamda.2019.01.119. Epub 2019 Mar 1. PubMed PMID: 30827893.
34. Kokts-Porietis RL, Stone CR, **Friedenreich CM**, Froese A, **McDonough M**, McNeil J. Breast cancer survivors' perspectives on a home-based physical activity intervention utilizing wearable technology. *Support Care Cancer*. 2019 Aug;27(8):2885-2892. doi: 10.1007/s00520-018-4581-7. Epub 2018 Dec 15. PubMed PMID: 30554276.
35. Stone CR, Courneya KS, McGregor SE, Li H, **Friedenreich CM**. Determinants of changes in physical activity from pre-diagnosis to post-diagnosis in a cohort of prostate cancer survivors. *Support Care Cancer*. 2019 Aug;27(8):2819-2828. doi: 10.1007/s00520-018-4578-2. Epub 2018 Dec 12. PubMed PMID: 30543049.
36. **McDonough MH**, Patterson MC, Weisenbach BB, Ullrich-French S, Sabiston CM. The difference is more than floating: factors affecting breast cancer survivors' decisions to join and maintain participation in dragon boat teams and support groups. *Disabil Rehabil*. 2019 Jul;41(15):1788-1796. doi: 10.1080/09638288.2018.1449259. Epub 2018 Mar 9. PubMed PMID: 29521150.



## **Health Services/Implementation Research**

1. **Cuthbert CA**, Watson L, Xu Y, Boyne DJ, Hemmelgarn BR, **Cheung WY**. Patient-reported outcomes in Alberta: rationale, scope, and design of a database initiative. *Curr Oncol*. 2019 Aug;26(4):e503-e509. doi: 10.3747/co.26.4919. Epub 2019 Aug 1. PubMed PMID: 31548818; PubMed Central PMCID: PMC6726254.
2. O'Brien MA, Makuwaza T, Graham ID, **Barbera L**, Earle CC, Brouwers MC, Grunfeld E. Lessons learned from a cancer knowledge translation grants program: results of an evaluation. *Curr Oncol*. 2019 Aug;26(4):272-284. doi: 10.3747/co.26.5531. Epub 2019 Aug 1. PubMed PMID: 31548808; PubMed Central PMCID: PMC6726260.
3. Nyhof BB, Wright FC, Look Hong NJ, Groot G, Helyer L, Meiers P, **Quan ML**, Baxter NN, Urquhart R, Warburton R, Gagliardi AR. Recommendations to improve patient-centred care for ductal carcinoma in situ: Qualitative focus groups with women. *Health Expect*. 2019 Sep 18. doi: 10.1111/hex.12973. [Epub ahead of print] PubMed PMID: 31532871.
4. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TÅ, Tervonen H, Thursfield V, Ransom D, **Shack L**, Woods RR, Turner D, Leonfellner S, Ryan S, Saint-Jacques N, De P, McClure C, Ramanakumar AV, Stuart-Panko H, Engholm G, Walsh PM, Jackson C, Vernon S, Morgan E, Gavin A, Morrison DS, Huws DW, Porter G, Butler J, Bryant H, Currow DC, Hiom S, Parkin DM, Sasieni P, Lambert PC, Møller B, Soerjomataram I, Bray F. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. *Lancet Oncol*. 2019 Sep 11. pii: S1470-2045(19)30456-5. doi: 10.1016/S1470-2045(19)30456-5. PubMed PMID: 31521509.
5. **Cuthbert CA**, Farragher JF, Hemmelgarn BR, Ding Q, McKinnon GP, **Cheung WY**. Self-management Interventions for Cancer Survivors: A Systematic Review and Evaluation of Intervention Content and Theories. *Psychooncology*. 2019 Sep 2. doi: 10.1002/pon.5215. [Epub ahead of print] Review. PubMed PMID: 31475766.
6. **Karim S**, Mackillop WJ, Brennan K, Peng Y, Siemens DR, Krzyzanowska MK, Booth CM. Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. *Cancer Med*. 2019 Aug. doi: 10.1002/cam4.2449. PMID: 31472011.
7. Pham TM, Shack L, **Cheung WY**. Introduction of a novel measure of premature mortality caused by chronic conditions: real-world examples from prostate and testis cancers in Canada, 1980-2015. *Ann Epidemiol*. 2019 Sep;37:81-83. doi: 10.1016/j.annepidem.2019.07.011. Epub 2019 Jul 26. PubMed PMID: 31427150.
8. **Karim S**, Booth CM, Brennan K, Peng Y, Siemens DR, Krzyzanowska MK, Mackillop WJ. Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer. *Cancer Med*. 2019 Sep;8(12):5590-5599. doi: 10.1002/cam4.2456. Epub 2019 Aug 12. PubMed PMID: 31407518; PubMed Central PMCID: PMC6745837.
9. Henderson JD, Boyle A, Herx L, Alexiadis A, Barwich D, Connidis S, Lysecki D, **Sinnarajah A**. Staffing a Specialist Palliative Care Service, a Team-Based Approach: Expert Consensus White Paper. *J Palliat Med*. 2019 Jul. doi: 10.1089/jpm.2019.0314. PMID: 31347940.
10. Keehn AR, Olson DW, **Dort JC**, Parker S, Anderes S, Headley L, Elwi A, Estey A, Crocker A, Laws A, **Quan ML**. Same-Day Surgery for Mastectomy Patients in Alberta: A Perioperative Care Pathway and Quality Improvement Initiative. *Ann Surg Oncol*. 2019 Oct;26(10):3354-3360. doi: 10.1245/s10434-019-07568-5. Epub 2019 Jul 24. PubMed PMID: 31342384.

## **Health Services/Implementation Research (continued)**

11. Laws A, Crocker A, **Dort J**, Olson D, Elwi A, Anderes S, Parker S, Estey A, Keehn A, **Quan ML**. Improving Wait Times and Patient Experience Through Implementation of a Provincial Expedited Diagnostic Pathway for BI-RADS 5 Breast Lesions. *Ann Surg Oncol*. 2019 Oct;26(10):3361-3367. doi: 10.1245/s10434-019-07558-7. PMID: 31342368.
12. Gibson AJW, Li H, D'Silva A, Elegbede AA, Tudor RA, Otsuka S, **Bebb DG**, **Cheung WY**. Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study. *Lung Cancer*. 2019 Aug;134:141-146. doi: 10.1016/j.lungcan.2019.06.003. PubMed PMID: 31319972.
13. Sutradhar R, Rostami M, **Barbera L**. Patient-Reported Symptoms Improve Performance of Risk Prediction Models for Emergency Department Visits Among Patients With Cancer: A Population-Wide Study in Ontario Using Administrative Data. *J Pain Symptom Manage*. 2019 Jul 16. pii: S0885-3924(19)30380-X. doi: 10.1016/j.jpainsymman.2019.07.007. [Epub ahead of print] PubMed PMID: 31319103.
14. Hammad A, Davis LE, Mahar AL, Bubis LD, Zhao H, Earle CC, **Barbera L**, Hallet J, Coburn NG. Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life: a population based analysis of 2,538 patients. *HPB (Oxford)*. 2019 Jul 9. pii: S1365-182X(19)30537-4. doi: 10.1016/j.hpb.2019.04.016. [Epub ahead of print] PubMed PMID: 31300337.
15. **Karim S**, Xu Y, Kong S, Abdel-Rahman O, **Quan ML**, **Cheung WY**. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World. *Clin Oncol (R Coll Radiol)*. 2019 Sep;31(9):e160-e166. doi: 10.1016/j.clon.2019.05.003. PMID: 31133363.  
**Hinther A**, Abdel-Rahman O, **Cheung WY**, **Quan ML**, **Dort JC**. Chronic Postoperative Opioid Use: A Systematic Review. *World J Surg*. 2019 Sep;43(9):2164-2174. doi: 10.1007/s00268-019-05016-9. Epub 2019 May 9. Review. PubMed PMID: 31073685.
16. **Abdul-Razzak A**, Lemieux L, Snyman M, Perez G, **Sinnarajah A**. Description of Continuous Palliative Sedation Practices in a Large Health Region and Comparison with Clinical Practice Guidelines. *J Palliat Med*. 2019 Sep;22(9):1052-1064. doi: 10.1089/jpm.2018.0372. Epub 2019 Apr 2. PubMed PMID: 30939060.
17. Ellaway RH, Malhi RL, Woloschuk W, **de Groot JM**, Doig CJ, Myhre D. An Axiological Analysis of One Medical School's Admissions Process: Exploring Individual Values and Value Systems. *Acad Med*. 2019;94(8):1229-36. doi: 10.1097/ACM.0000000000002698.
18. **Barbera L**, Sutradhar R, Howell D, Corn E, O'Brien MA, Seow H, Dudgeon D, Atzema C, Earle CC, DeAngelis C, Sussman J. Factors Associated With Opioid Use in Long-term Cancer Survivors. *J Pain Symptom Manage*. 2019 Jul;58(1):100-107.e2. doi: 10.1016/j.jpainsymman.2019.02.024. Epub 2019 Mar 2. PubMed PMID: 30831238.
19. Xu Y, Kong S, **Cheung WY**, **Quan ML**, Nakoneshny SC, **Dort JC**. Developing case-finding algorithms for second events of oropharyngeal cancer using administrative data: A population-based validation study. *Head Neck*. 2019 Jul;41(7):2291-2298. doi: 10.1002/hed.25682. Epub 2019 Feb 1. PubMed PMID: 30706597.
20. Read Paul L, Salmon C, **Sinnarajah A**, Spice R. Web-based videoconferencing for rural palliative care consultation with elderly patients at home. *Support Care Cancer*. 2019 Sep;27(9):3321-3330. doi: 10.1007/s00520-018-4580-8. PMID: 30613908.

## **Basic/Biomedical Research**

1. Fuladpanjeh-Hojaghan B, Elsutohy MM, Kabanov V, **Heyne B**, Trifkovic M, Roberts EPL. In-operando mapping of pH distribution in electrochemical processes. *Angew Chem Int Ed Engl*. 2019 Sep 19. doi: 10.1002/anie.201909238. PubMed PMID: 31538391.
2. Le NDB, Singla AK, Geng Y, Han J, Seehafer K, Prakash G, Moyano DF, Downey CM, **Monument MJ**, Itani D, Bunz UHF, Jirik FR, Rotello VM. Simple and robust polymer-based sensor for rapid cancer detection using serum. *Chem Commun (Camb)*. 2019 Sep 19;55(76):11458-11461. doi: 10.1039/c9cc04854e. PubMed PMID: 31535684.
3. Dong Y, **Yong VW**. When encephalitogenic T cells collaborate with microglia in multiple sclerosis. *Nat Rev Neurol*. 2019 Sep 16. doi: 10.1038/s41582-019-0253-6. [Epub ahead of print] Review. PubMed PMID: 31527807.
4. Xie W, Li L, Gong D, Zhang M, Lv YC, Guo DM, Zhao ZW, **Zheng XL**, Zhang DW, Dai XY, Yin WD, Tang CK. Krüppel-like factor 14 inhibits atherosclerosis via mir-27a-mediated down-regulation of lipoprotein lipase expression in vivo. *Atherosclerosis*. 2019 Aug 26;289:143-161. doi: 10.1016/j.atherosclerosis.2019.08.012. PubMed PMID: 31518965.
5. Sarpong-Kumankomah S, **Gailer J**. Identification of a haptoglobin-hemoglobin complex in human blood plasma. *J Inorg Biochem*. 2019 Aug 19;201:110802. doi: 10.1016/j.jinorgbio.2019.110802. [Epub ahead of print] PubMed PMID: 31514091.
6. Rafiei A, **Schriemer DC**. A microtubule crosslinking protocol for integrative structural modeling activities. *Anal Biochem*. 2019 Sep 6;586:113416. doi: 10.1016/j.ab.2019.113416. [Epub ahead of print] PubMed PMID: 31499019.
7. Guo LY, Lozinski B, **Yong VW**. Exercise in multiple sclerosis and its models: Focus on the central nervous system outcomes. *J Neurosci Res*. 2019 Sep 4. doi: 10.1002/jnr.24524. [Epub ahead of print] Review. PubMed PMID: 31486115.
8. Xu X, Li J, Zou J, Feng X, Zhang C, Zheng R, Duanmu W, Saha-Mandal A, Ming Z, **Wang E**. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk. *JAMA Netw Open*. 2019 Sep 4;2(9):e199292. doi: 10.1001/jamanetworkopen.2019.9292. PMID: 31483464; PMCID: PMC6727785.
9. Jette NR, Radhamani S, Arthur G, Ye R, Goutam S, Bolyos A, Petersen LF, **Bose P**, **Bebb DG**, **Lees-Miller SP**. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells. *Br J Cancer*. 2019 Sep. doi: 10.1038/s41416-019-0565-8. PMID: 31481733.
10. Azarmanesh M, Bawazeer S, Mohamad AA, **Sanati-Nezhad A**. Rapid and Highly Controlled Generation of Monodisperse Multiple Emulsions via a One-Step Hybrid Microfluidic Device. *Sci Rep*. 2019 Sep 3;9(1):12694. doi: 10.1038/s41598-019-49136-7. PubMed PMID: 31481702; PubMed Central PMCID: PMC6722102.
11. Zhang L, He X, Liu X, Zhang F, Huang LF, Potter AS, ... **Morrissey AS**, ... Xin M, Taylor MD, Potter SS, Roussel MF, Weiss WA, Lu QR. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. *Cancer Cell*. 2019 Sep 16;36(3):302-318.e7. doi: 10.1016/j.ccell.2019.07.009. Epub 2019 Aug 29. PubMed PMID: 31474569.



## **Basic/Biomedical Research (continued)**

12. Shen Y, Grisdale CJ, Islam SA, **Bose P**, Lever J, Zhao EY, Grinshtein N, Ma Y, Mungall AJ, Moore RA, Lun X, **Senger DL**, **Robbins SM**, Wang AY, MacIsaac JL, Kobor MS, **Luchman HA**, **Weiss S**, **Chan JA**, **Blough MD**, Kaplan DR, **Cairncross JG**, Marra MA, Jones SJM. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. *Proc Natl Acad Sci U S A*. 2019 Sep 17;116(38):19098-19108. doi: 10.1073/pnas.1813495116. PMID: 31471491.
13. Choudhury SR, Babes L, Rahn JJ, Ahn BY, Goring KR, King JC, Lau A, Petri B, Hao X, Chojnacki AK, Thanabalasuriar A, McAvoy EF, Tabariès S, Schraeder C, Patel KD, Siegel PM, **Kopciuk KA**, **Schriemer DC**, Muruve DA, Kelly MM, Yipp BG, Kubes P, **Robbins SM**, **Senger DL**. Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver. *Cell*. 2019 Aug;178(5):1205-21.e17. doi: 10.1016/j.cell.2019.07.017. PubMed PMID: 31442408.
14. Otterbein H, Mihara K, **Hollenberg MD**, Lehnert H, Witte D, Ungefroren H. RAC1B Suppresses TGF- $\beta$ -Dependent Chemokinesis and Growth Inhibition through an Autoregulatory Feed-Forward Loop Involving PAR2 and ALK5. *Cancers (Basel)*. 2019 Aug 20;11(8). pii: E1211. doi: 10.3390/cancers11081211. PubMed PMID: 31434318; PubMed Central PMCID: PMC6721813.
15. Stephenson EL, Zhang P, Ghorbani S, Wang A, Gu J, Keough MB, Rawji KS, Silva C, **Yong VW**, Ling CC. Targeting the Chondroitin Sulfate Proteoglycans: Evaluating Fluorinated Glucosamines and Xylosides in Screens Pertinent to Multiple Sclerosis. *ACS Cent Sci*. 2019 Jul 24;5(7):1223-1234. doi: 10.1021/acscentsci.9b00327. Epub 2019 May 30. PubMed PMID: 31404231; PubMed Central PMCID: PMC6661872.
16. Zhou Y, Millott R, Kim HJ, Peng S, Edwards RA, Skene-Arnold T, Hammel M, **Lees-Miller SP**, Tainer JA, Holmes CFB, Glover JNM. Flexible Tethering of ASPP Proteins Facilitates PP-1c Catalysis. *Structure*. 2019 Aug 6. pii: S0969-2126(19)30244-8. doi: 10.1016/j.str.2019.07.012. [Epub ahead of print] PubMed PMID: 31402222.
17. Faissner S, Plemel JR, Gold R, **Yong VW**. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. *Nat Rev Drug Discov*. 2019 Aug 9. doi: 10.1038/s41573-019-0035-2. [Epub ahead of print] Review. PubMed PMID: 31399729.
18. Borys BS, Le A, Roberts EL, Dang T, Rohani L, Hsu CY, Wyma AA, **Rancourt DE**, Gates ID, Kallos MS. Using computational fluid dynamics (CFD) modeling to understand murine embryonic stem cell aggregate size and pluripotency distributions in stirred suspension bioreactors. *J Biotechnol*. 2019 Oct 10;304:16-27. doi: 10.1016/j.jbiotec.2019.08.002. Epub 2019 Aug 5. PubMed PMID: 31394111.
19. Mojumdar A, Sorenson K, Hohl M, Toulouze M, **Lees-Miller SP**, Dubrana K, Petrini JHJ, **Cobb JA**. Nej1 Interacts with Mre11 to Regulate Tethering and Dna2 Binding at DNA Double-Strand Breaks. *Cell Rep*. 2019 Aug 6;28(6):1564-1573.e3. doi: 10.1016/j.celrep.2019.07.018. PMID: 31390569; PMCID: PMC6746346.
20. Sarkar A, Chanda A, Regmi SC, Karve K, Deng L, Jay GD, **Jirik FR**, Schmidt TA, **Bonni S**. Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGF $\beta$ -Hyaluronan-CD44 signalling pathway. *PLoS One*. 2019 Jul;14(7):e0219697. doi: 10.1371/journal.pone.0219697. PMID: 31361756; PMCID: PMC6667139.

## **Basic/Biomedical Research (continued)**

21. Motta JP, Denadai-Souza A, Sagnat D, Guiraud L, Edir A, Bonnart C, ... **Hollenberg MD**, Oswald E, Serino M, Deraison C, Vergnolle N. Active thrombin produced by the intestinal epithelium controls mucosal biofilms. *Nat Commun*. 2019 Jul 19;10(1):3224. doi: 10.1038/s41467-019-11140-w. PMID: 31324782; PMCID: PMC6642099.
22. Camara-Lemarroy CR, Silva C, Greenfield J, Liu WQ, Metz LM, **Yong VW**. Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity. *Mult Scler*. 2019 Jul;1352458519863133. doi: 10.1177/1352458519863133. PMID: 31317818.
23. Tsujikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, Sarsons CD, Gilham D, Daze E, Wasiak S, Studer D, **Rinker KD**, Sweeney M, Johansson JO, Wong NCW, Kulikowski E. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. *Clin Epigenetics*. 2019 Jul 12;11(1):102. doi: 10.1186/s13148-019-0696-z. PMID: 31300040; PMCID: PMC6626370.
24. Schreier TB, Umhang M, Lee SK, Lue WL, Shen Z, Silver D, Graf A, Müller A, Eicke S, Stadler-Waibel M, Seung D, Bischof S, Briggs SP, Kötting O, **Moorhead GBG**, Chen J, Zeeman SC. LIKE SEX4 1 Acts as a  $\beta$ -Amylase-Binding Scaffold on Starch Granules during Starch Degradation. *Plant Cell*. 2019 Sep;31(9):2169-2186. doi: 10.1105/tpc.19.00089. Epub 2019 Jul 2. PubMed PMID: 31266901.
25. Swift L, Zhang C, **Kovalchuk O**, Boklan J, Trippett T, **Narendran A**. Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma. *Invest New Drugs*. 2019 Jul 2. doi: 10.1007/s10637-019-00816-1. PMID: 31264069.
26. Lee PS, Hess R, Friedrichs J, Haenchen V, Eckert H, Cuniberti G, **Rancourt D**, Krawetz R, Hintze V, Gelinsky M, Scharnweber D. Recapitulating bone development events in a customised bioreactor through interplay of oxygen tension, medium pH, and systematic differentiation approaches. *J Tissue Eng Regen Med*. 2019 Sep;13(9):1672-1684. doi: 10.1002/term.2921. Epub 2019 Jul 15. PubMed PMID: 31250556.
27. Masson GR, Burke JE, Ahn NG, Anand GS, Borchers C, Brier S, ... **Schriemer DC**, Rand KD. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. *Nat Methods*. 2019 Jul; 16(7):595-602. doi: 10.1038/s41592-019-0459-y. PMID: 31249422; PMCID: PMC6614034.
28. Johnston MJ, Nikolic A, Ninkovic N, Guilhamon P, Cavalli FMG, Seaman S, Zemp FJ, Lee J, Abdelkareem A, Ellestad K, Murison A, Kushida MM, Coutinho FJ, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Dirks PB, Pugh TJ, **Morrissey S**, St Croix B, **Mahoney DJ**, Lupien M, **Gallo M**. High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. *Genome Res*. 2019 Aug;29(8):1211-1222. doi: 10.1101/gr.246520.118. Epub 2019 Jun 27. PubMed PMID: 31249064; PubMed Central PMCID: PMC6673710.
29. Shamsi M, Mohammadi A, Manshadi MKD, **Sanati-Nezhad A**. Mathematical and computational modeling of nano-engineered drug delivery systems. *J Control Release*. 2019 Aug 10;307:150-165. doi: 10.1016/j.jconrel.2019.06.014. PMID: 31229474.
30. Enriquez Garcia A, Lai B, Gopinathan SG, Harris HH, **Shemanko CS**, Jalilehvand F. Nuclear localization of dirhodium(II) complexes in breast cancer cells by X-ray fluorescence microscopy. *Chem Commun (Camb)*. 2019 Jul 11;55(57):8223-8226. doi: 10.1039/c9cc00521h. PubMed PMID: 31215918.

### **Basic/Biomedical Research (continued)**

31. Pulakazhi Venu VK, Saifeddine M, Mihara K, Tsai YC, Nieves K, Alston L, Mani S, McCoy KD, **Hollenberg MD**, Hirota SA. The pregnane X receptor and its microbiota-derived ligand indole 3-propionic acid regulate endothelium-dependent vasodilation. *Am J Physiol Endocrinol Metab.* 2019 Aug 1;317(2):E350-E361. doi: 10.1152/ajpendo.00572.2018. Epub 2019 Jun 18. PubMed PMID: 31211619; PubMed Central PMCID: PMC6732469.
32. Huang M, Tailor J, Zhen Q, Gillmor AH, Miller ML, Weishaupt H, ... **Morrissey AS**, Kool M, Pfister SM, Taylor MD, Smith A, Weiss WA. Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. *Cell Stem Cell.* 2019 Sep;25(3):433-446.e7. doi: 10.1016/j.stem.2019.05.013. PMID: 31204176.
33. Nourbakhsh M, Mansoor A, Koro K, **Zhang Q**, **Minoo P**. Expression Profiling Reveals Involvement of WNT Pathway in the Malignant Progression of Sessile Serrated Adenomas. *Am J Pathol.* 2019 Sep;189(9):1732-1743. doi: 10.1016/j.ajpath.2019.05.009. Epub 2019 Jun 11. PubMed PMID: 31199922.
34. Whitesell TR, Chrystal PW, Ryu JR, Munsie N, Grosse A, French CR, Workentine ML, Li R, Zhu LJ, Waskiewicz A, Lehmann OJ, Lawson ND, **Childs SJ**. foxc1 is required for embryonic head vascular smooth muscle differentiation in zebrafish. *Dev Biol.* 2019 Sep 1;453(1):34-47. doi: 10.1016/j.ydbio.2019.06.005. Epub 2019 Jun 11. PubMed PMID: 31199900.
35. Macia N, Kabanov V, Côté-Cyr M, **Heyne B**. Roles of Near and Far Fields in Plasmon-Enhanced Singlet Oxygen Production. *J Phys Chem Lett.* 2019 Jul 5;10(13):3654-3660. doi: 10.1021/acs.jpclett.9b01165. Epub 2019 Jun 18. PubMed PMID: 31194564.
36. Zhou G, **Hollenberg MD**, Vliagoftis H, Kane KP. Protease-Activated Receptor 2 Agonist as Adjuvant: Augmenting Development of Protective Memory CD8 T Cell Responses Induced by Influenza Virosomes. *J Immunol.* 2019 Jul 15;203(2):441-452. doi: 10.4049/jimmunol.1800915. Epub 2019 Jun 10. PubMed PMID: 31182479.
37. Koch MW, Liu WQ, Camara-Lemarroy C, Zhang Y, Pike GB, Metz L, **Yong VW**. Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis. *J Neuroimmunol.* 2019 Sep 15;334:576974. doi: 10.1016/j.jneuroim.2019.576974. Epub 2019 May 29. PubMed PMID: 31174092.
38. Vladiu MC, El-Hamamy I, Donovan LK, Farooq H, Holgado BL, Sundaravadanam Y, ... **Morrissey AS**, ... Thompson EM, Kleinman CL, Joyner AL, Jabado N, Stein L, Taylor MD. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. *Nature.* 2019 Aug;572(7767):67-73. doi: 10.1038/s41586-019-1158-7. Epub 2019 May 1. PubMed PMID: 31043743; PubMed Central PMCID: PMC6675628.
39. Hews-Girard J, **Poon MC**, Goodyear MD. Effect of an electronic treatment plan on acute management of hereditary angioedema. *Ann Allergy Asthma Immunol.* 2019 Jul;123(1):98-100. doi: 10.1016/j.anai.2019.04.013. PubMed PMID: 31004749.
40. Jayanthan A, Hofmann B, Meier-Stephenson V, Perinpanayagam M, Dunn SE, Boklan J, Trippett TM, **Truong TH**, **Narendran A**. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. *J Pediatr Hematol Oncol.* 2019 Aug;41(6):e359-e370. doi: 10.1097/MPH.0000000000001416. PubMed PMID: 30702467.



## **Translational and Clinical Research**

1. **Bebb DG**, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leigh NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS. Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective. *Curr Oncol*. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1. PubMed PMID: 31548824; PubMed Central PMCID: PMC6726257.
2. Roy S, **Hyndman ME**, Danielson B, Fairey A, Lee-Ying R, **Cheung WY**, Afzal AR, Xu Y, Abedin T, Quon HC. Active treatment in low-risk prostate cancer: a population-based study. *Curr Oncol*. 2019 Aug;26(4):e535-e540. doi: 10.3747/co.26.4953. Epub 2019 Aug 1. PubMed PMID: 31548822; PubMed Central PMCID: PMC6726256.
3. Dabas R, Khan PD, Modi M, **Khan FM**, **Storek J**. More acute lymphoid leukemia than acute myeloid leukemia blasts are killed by rabbit antithymocyte globulin. *Cytotherapy*. 2019 Sep 19. pii: S1465-3249(19)30842-4. doi: 10.1016/j.jcyt.2019.08.003. PMID: 31543396.
4. Forbes N, **Hilsden RJ**, Kaplan GG, James MT, Lethebe C, Maxwell C, Heitman SJ. Practice patterns and predictors of prophylactic endoscopic clip usage during polypectomy. *Endosc Int Open*. 2019 Sep;7(9):E1051-E1060. doi: 10.1055/a-0953-1787. Epub 2019 Aug 29. PubMed PMID: 31528686; PubMed Central PMCID: PMC6746303.
5. Zotz RB, **Poon MC**, Di Minno G, D'Oiron R; Glanzmann Thrombasthenia Registry Investigators . The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes. *TH Open*. 2019 Sep 12;3(3):e286-e294. doi: 10.1055/s-0039-1696657. eCollection 2019 Jul. PMID: 31523745; PMCID: PMC6742499.
6. Martell K, **Doll C**, Barnes EA, Phan T, Leung E, Taggar A. Radiotherapy practices in postoperative endometrial cancer: A survey of the ABS membership. *Brachytherapy*. 2019 Sep 11. pii: S1538-4721(19)30438-6. doi: 10.1016/j.brachy.2019.07.004. PMID: 31521546.
7. Anoveros-Barrera A, Bhullar AS, Stretch C, Dunichand-Hoedl AR, Martins KJB, Rieger A, Bigam D, McMullen T, **Bathe OF**, Putman CT, Field CJ, Baracos VE, Mazurak VC. Immunohistochemical phenotyping of T cells, granulocytes, and phagocytes in the muscle of cancer patients: association with radiologically defined muscle mass and gene expression. *Skelet Muscle*. 2019 Sep 14;9(1):24. doi: 10.1186/s13395-019-0209-y. PubMed PMID: 31521204; PubMed Central PMCID: PMC6744687.
8. Bisch SP, Kooy J, Glaze S, Cameron A, **Chu P**, **Ghatage P**, Nation J, **Nelson G**, Fitzmaurice GM. Impact of transversus abdominis plane blocks versus non-steroidal anti-inflammatory on post-operative opioid use in ERAS ovarian cancer surgery. *Int J Gynecol Cancer*. 2019 Sep 11. pii: ijgc-2019-000724. doi: 10.1136/ijgc-2019-000724. PMID: 31515412.
9. Opoku-Darko M, Eagles ME, Cadieux M, Isaacs AM, **Kelly JJP**. Natural history and growth patterns of incidentally discovered diffusely infiltrating low-grade gliomas: A volumetric study. *World Neurosurg*. 2019 Sep 7. pii: S1878-8750(19)32402-7. doi: 10.1016/j.wneu.2019.08.235. [Epub ahead of print] PubMed PMID: 31505287.
10. Kebriaei P, Hayes J, **Daly A**, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall E, Martin PJ. A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease. *Biol Blood Marrow Transplant*. 2019 Sep 7. pii: S1083-8791(19)30573-7. doi: 10.1016/j.bbmt.2019.08.029. [Epub ahead of print] PubMed PMID: 31505228.

### **Translational and Clinical Research (continued)**

11. Nguyen LT, Guo M, Hemmelgarn B, Quan H, Clement F, Sajobi T, Thomas R, Turin TC, **Naugler C**. Dataset of clinical laboratory tests according to ordering variance among family physicians in Calgary, Alberta, Canada. Data Brief. 2019 Aug 12;25:104387. doi: 10.1016/j.dib.2019.104387. PMID: 31489358; PubMed Central PMCID: PMC6717211.
12. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, **Tam VC**, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balietti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print] PubMed PMID: 31486832.
13. Bush SH, Roze des Ordons A, **Chary S**, Boyle AB. The Development and Validation of Updated Palliative and End-of-Life Care Competencies for Medical Undergraduates in Canada. J Palliat Med. 2019 Sep 5. doi: 10.1089/jpm.2019.0160. PMID: 31486699.
14. Gibson AJW, D'Silva A, Elegbede AA, Tudor RA, Dean ML, **Bebb DG**, **Hao D**. Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer. Asia Pac J Clin Oncol. 2019 Sep 4. doi: 10.1111/ajco.13234. PMID: 31486229.
15. **Nixon NA**, Simmons C, Lemieux J, **Verma S**. Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership. Breast J. 2019 Sep 2. doi: 10.1111/tbj.13525. [Epub ahead of print] PubMed PMID: 31478296.
16. **Abdul-Razzak A**, Murray A, Duplessis S. Surgical cordotomy helps psychosocial suffering. BMJ Support Palliat Care. 2019 Aug 31. pii: bmjcare-2019-001886. doi: 10.1136/bmjcare-2019-001886. [Epub ahead of print] PubMed PMID: 31473649.
17. Hernandez-Torres C, **Cheung WY**, Kong S, O'Callaghan CJ, Hsu T. Accrual of older adults to cancer clinical trials led by the Canadian cancer trials group - Is trial design a barrier? J Geriatr Oncol. 2019 Aug 28. pii: S1879-4068(19)30145-6. doi: 10.1016/j.jgo.2019.08.004. PMID: 31473189.
18. Ustun C, Kim S, Chen M, Beitinjane AM, Brown VI, Dahi PB, **Daly A**, et al. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Adv. 2019 Sep;3(17):2525-36. doi: 10.1182/bloodadvances.2019000226. PubMed PMID: 31471322; PubMed Central PMCID: PMC6737406.
19. Arena R, Rouleau CR, **Campbell TS**, Aggarwal S, Hauer T, Wilton SB, Stone J, Laddu D, Ozemek C, Williamson TM, Liu H, Austford LD. Integrating Science, Practice, and Mentorship in Cardiac Rehabilitation: THE INAUGURAL TOTALCARDIOLOGY® RESEARCH NETWORK RETREAT. J Cardiopulm Rehabil Prev. 2019 Sep;39(5):290-292. doi: 10.1097/HCR.0000000000000470. PubMed PMID: 31464884.
20. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, **Bismar TA**, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2019 Aug 27. doi: 10.1038/s41391-019-0167-9. [Epub ahead of print] PubMed PMID: 31455846.

### **Translational and Clinical Research (continued)**

21. Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, **Heng DYC**. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. *Eur Urol*. 2019 Aug 22. pii: S0302-2838(19)30609-8. doi: 10.1016/j.eururo.2019.07.048. PMID: 31445844.
22. Pang G, Look Hong NJ, Paull G, Dobransky J, Kupper S, Hurton S, Kagedan DJ, **Quan ML**, Helyer L, Nessim C, Wright FC. Squamous Cell Carcinoma with Regional Metastasis to Axilla or Groin Lymph Nodes: a Multicenter Outcome Analysis. *Ann Surg Oncol*. 2019 Aug 22. doi: 10.1245/s10434-019-07743-8. [Epub ahead of print] PubMed PMID: 31440926.
23. **Olivetto IA**, Link E, Phillips C, Whelan TJ, Bryant G, Kunkler IH, Westenberg AH, Purohit K, Ahern V, Graham PH, Akra M, McArdle O, Ludbrook JJ, Harvey JA, Maduro JH, Kirkove C, Gruber G, Martin JD, Campbell ID, Delaney GP, Chua BH; BIG 03-07/TROG 07.01 trial investigators. International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. *Radiother Oncol*. 2019 Aug 17. pii: S0167-8140(19)33017-8. doi: 10.1016/j.radonc.2019.07.024. [Epub ahead of print] PubMed PMID: 31431385.
24. Bubis LD, Davis LE, Canaj H, Gupta V, Jeong Y, **Barbera L**, Li Q, Moody L, Karanicolas PJ, Sutradhar R, Coburn NG, Mahar AL. Patient-reported symptom severity among 22,650 cancer outpatients in the last 6 months of life. *J Pain Symptom Manage*. 2019 Aug 17. pii: S0885-3924(19)30462-2. doi: 10.1016/j.jpainsymman.2019.08.016. PMID: 31430522.
25. Duimering A, **Walker LM**, Turner J, Andrews-Lepine E, Driga A, Ayume A, **Robinson JW**, Wiebe E. Quality improvement in sexual health care for oncology patients: a Canadian multidisciplinary clinic experience. *Support Care Cancer*. 2019 Aug 19. doi: 10.1007/s00520-019-05040-4. [Epub ahead of print] PubMed PMID: 31428930.
26. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, ... **Heng DYC**, ... Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2019 Aug 16. pii: S1470-2045(19)30413-9. doi: 10.1016/S1470-2045(19)30413-9. PMID: 31427204.
27. Roze des Ordons AL, Stelfox HT, Sinuff T, Grindrod-Millar K, Smiechowski J, **Sinclair S**. Spiritual Distress in Family Members of Critically Ill Patients: Perceptions and Experiences. *J Palliat Med*. 2019 Aug 13. doi: 10.1089/jpm.2019.0235. PMID: 31408405.
28. Letourneau NL, de Koning APJ, Sekhon B, Ntanda HN, Kobor M, Deane AJ, Morin AM, Dewey D, **Campbell TS**, Giesbrecht GF; APrON Study Team. Parenting Interacts With Plasticity Genes in Predicting Behavioral Outcomes in Preschoolers. *Can J Nurs Res*. 2019 Aug 12:844562119863612. doi: 10.1177/0844562119863612. PMID: 31403319.
29. Berger BM, Kisiel JB, Imperiale TF, Geenen DJ, Heigh RI, **Mahoney DW**, **Hilsden RJ**. Low Incidence of Aerodigestive Cancers in Patients With Negative Results From Colonoscopies, Regardless of Findings From Multitarget Stool DNA Tests. *Clin Gastroenterol Hepatol*. 2019 Aug. pii: S1542-3565(19)30846-8. doi: 10.1016/j.cgh.2019.07.057. PMID: 31394289.



### **Translational and Clinical Research (continued)**

30. Pergam SA, Englund JA, Kamboj M, Gans HA, Young JH, Hill JA, Savani B, Chemaly RF, Dadwal SS, **Storek J**, Duchin J, Carpenter PA. Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2019 Aug 5. pii: S1083-8791(19)30506-3. doi: 10.1016/j.bbmt.2019.07.034. [Epub ahead of print] Review. PubMed PMID: 31394271.
31. Alaghebandan R, Vanecek T, **Trpkov K**, Comperat E, Kristiansen G, Svajdler M, Cempirkova D, Pavlovsky M, Pivovarcikova K, Stehlikova A, Hora M, Michal M, Hes O. High-grade Adenocarcinoma of the Prostate Mimicking Urothelial Carcinoma is Negative for TERT Mutations. *Appl Immunohistochem Mol Morphol*. 2019 Aug;27(7):523-528. doi: 10.1097/PAI.0000000000000588. PubMed PMID: 31393284.
32. Veitch Z, Khan OF, Tilley D, **Tang PA**, Ribnikar D, **Stewart DA**, Kostaras X, King K, **Lupichuk S**. Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer. *J Natl Compr Canc Netw*. 2019 Aug 1;17(8):957-967. doi: 10.6004/jnccn.2019.7286. PubMed PMID: 31390594.
33. Truong TH, Prokopishyn NL, Luu H, **Guilcher GMT**, **Lewis VA**. Predictive factors for successful peripheral blood stem cell mobilization and collection in children. *J Clin Apher*. 2019 Oct;34(5):598-606. doi: 10.1002/jca.21738. PMID: 31390093.
34. Blosser N, Jupp J, Yau P, **Stewart D**. Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. *Clin Pharmacokinet*. 2019 Aug 6. doi: 10.1007/s40262-019-00807-8. [Epub ahead of print] Review. PubMed PMID: 31385204.
35. Kushnir I, Kirk L, Mallick R, Kim RH, Graham GE, Breau RH, Lattouf JB, Violette PD, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, **Heng DYC**, Basappa NS, So A, Pouliot F, Reaume NM. Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. *Clin Oncol (R Coll Radiol)*. 2019 Aug 1. pii: S0936-6555(19)30290-0. doi: 10.1016/j.clon.2019.07.010. PMID: 31378448.
36. de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, **Heng DYC**, Escudier B. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. *Eur Urol Oncol*. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. PMID: 31377308.
37. Roze des Ordons AL, **Sinclair S**, Sinuff T, Grindrod-Millar K, Stelfox HT. Development of a Clinical Guide for Identifying Spiritual Distress in Family Members of Patients in the Intensive Care Unit. *J Palliat Med*. 2019 Aug. doi: 10.1089/jpm.2019.0187. PMID: 31373867.
38. Hochmair MJ, Morabito A, **Hao D**, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. *Future Oncol*. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. PMID: 31370698.
39. Brennan L, **Narendran A**. Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia. *Stem Cells Dev*. 2019 Sep 17. doi: 10.1089/scd.2019.0035. [Epub ahead of print] PubMed PMID: 31364487.
40. Falegan OS, Arnold Egloff SA, Zijlstra A, **Hyndman ME**, **Vogel HJ**. Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas. *Metabolites*. 2019 Jul 24;9(8). pii: E155. doi: 10.3390/metabo9080155. PMID: 31344778; PMCID: PMC6724101.

### **Translational and Clinical Research (continued)**

41. Anoveros-Barrera A, Bhullar AS, Stretch C, Esfandiari N, Dunichand-Hoedl AR, Martins KJB, Bigam D, Khadaroo RG, McMullen T, **Bathe OF**, Damaraju S, Skipworth RJ, Putman CT, Baracos VE, Mazurak VC. Clinical and biological characterization of skeletal muscle tissue biopsies of surgical cancer patients. *J Cachexia Sarcopenia Muscle*. 2019 Jul 15. doi: 10.1002/jcsm.12466. [Epub ahead of print] PubMed PMID: 31307124.
42. Graham J, Bhindi B, **Heng DYC**. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma. *Curr Opin Urol*. 2019 Sep;29(5):507-512. doi: 10.1097/MOU.0000000000000657. PubMed PMID: 31305275.
43. McIntyre JB, Ko JJ, Siever J, Chan AMY, Simpson RHW, **Hao D**, Lau HY. MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study. *Diagn Pathol*. 2019 Jul 13;14(1):78. doi: 10.1186/s13000-019-0855-8. PubMed PMID: 31301736; PubMed Central PMCID: PMC6626627.
44. Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, ... **Daly A, Storek J**, ... Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. *Transpl Infect Dis*. 2019 Jul 12:e13145. doi: 10.1111/tid.13145.
45. Stukalin I, Gao Y, Spaner S, **Trpkov K, Gotto G**. Primary adenocarcinoma of bulbomembranous urethra: An exceedingly rare carcinoma in a male patient. *Urol Case Rep*. 2019 Jun 7;26:100941. doi: 10.1016/j.eucr.2019.100941. eCollection 2019 Sep. PubMed PMID: 31297328; PubMed Central PMCID: PMC6597530.
46. **Neri P**. The Pandora's box of thalidomide analogs and their substrates. *Blood*. 2019 Jul 11;134(2):105-106. doi: 10.1182/blood.2019001420. PubMed PMID: 31296542.
47. Forbes N, Frehlich L, James MT, **Hilsden RJ**, Kaplan GG, Wilson TA, Lorenzetti DL, Tate DJ, Bourke MJ, Heitman SJ. Routine Prophylactic Endoscopic Clipping Is Not Efficacious in the Prevention of Delayed Post-Polypectomy Bleeding: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Can Assoc Gastroenterol*. 2019 Aug;2(3):105-117. doi: 10.1093/jcag/gwy033. PMID: 31294373; PMCID: PMC6619410.
48. Gill VC, Ma I, Guo M, Gregson DB, **Naugler C**, Church DL. Sociodemographic and geospatial associations with community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) infections in a large Canadian city: an 11 year retrospective study. *BMC Public Health*. 2019 Jul 9;19(1):914. doi: 10.1186/s12889-019-7169-3. PubMed PMID: 31288765; PubMed Central PMCID: PMC6617829.
49. Sin-Chan P, Mumal I, Suwal T, Ho B, Fan X, Singh I, ... **Chan J, Lafay-Cousin L**, ... Li XN, Dirks PB, Lin CY, Mack SC, Rich JN, Huang A. A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. *Cancer Cell*. 2019 Jul 8;36(1):51-67.e7. doi: 10.1016/j.ccell.2019.06.002. PubMed PMID: 31287992. PubMed PMID: 30876675.
50. Nayan M, Jalali S, Kapoor A, Finelli A, So A, Rendon R, Breau RH, Lavallee LT, Tanguay S, **Heng D**, Kawakami J, Basappa NS, Bjarnason G, Pouliot F, Hamilton RJ. Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. *Urol Oncol*. 2019 Sep;37(9):576.e11-576.e16. doi: 10.1016/j.urolonc.2019.06.006. Epub 2019 Jul 5. PubMed PMID: 31285115.

### **Translational and Clinical Research (continued)**

52. Mann TD, Ploquin NP, Gill WR, Thind KS. Development and clinical implementation of eclipse scripting-based automated patient-specific collision avoidance software. *J Appl Clin Med Phys*. 2019 Sep;20(9):12-19. doi: 10.1002/acm2.12673. Epub 2019 Jul 7. PubMed PMID: 31282083; PubMed Central PMCID: PMC6753734.
53. Frederick A, Roumeliotis M, Grendarova P, Craighead P, Abedin T, Watt E, Olivotto IA, Meyer T, Quirk S. A Framework for Clinical Validation of Automatic Contour Propagation: Standardizing Geometric and Dosimetric Evaluation. *Pract Radiat Oncol*. 2019 Jul 4. pii: S1879-8500(19)30188-2. doi: 10.1016/j.prro.2019.06.017. PMID: 31279940.
54. Dudani S, Marginean H, Tang PA, Monzon JG, Raissouni S, Asmis TR, Goodwin RA, Gotfrit J, Cheung WY, Vickers MM. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. *BMC Cancer*. 2019 Jul 5;19(1):664. doi: 10.1186/s12885-019-5892-x. PMID: 31277604; PubMed Central PMCID: PMC6612202.
55. Tutelman PR, Chambers CT, Urquhart R, Fernandez CV, Heathcote LC, Noel M, Flanders A, Guilcher GMT, Schulte F, Stinson JN, MacLeod J, Stern M. When "a headache is not just a headache": A qualitative examination of parent and child experiences of pain after childhood cancer. *Psychooncology*. 2019 Sep;28(9):1901-1909. doi: 10.1002/pon.5170. Epub 2019 Jul 16. PubMed PMID: 31276614.
56. Hinther A, Samson N, Lau H, Quon H, Banerjee R, Lysack JT, Grendarova P, Matthews TW, Randall DR. Volumetric changes in pharyngeal structures following head and neck cancer chemoradiation therapy. *Laryngoscope*. 2019 Jul 1. doi: 10.1002/lary.28164.
57. Gupta M, Kannappan S, Kalra A, Lam C, Dharmani-Khan P, Williamson T, Tellier R, Daly A, Khan FM, Storek J. High incidence of hematologic malignancy relapse after allogeneic transplantation in patients with low Epstein-Barr virus-specific T-cell counts. *Cytotherapy*. 2019 Aug;21(8):886-894. doi: 10.1016/j.jcyt.2019.06.001. PMID: 31253496.
58. Reynolds K, Spavor M, Brandelli Y, Kwok C, Li Y, Disciglio M, Carlson LE, Schulte F, Anderson R, Grundy P, Giese-Davis J. A comparison of two models of follow-up care for adult survivors of childhood cancer. *J Cancer Surviv*. 2019 Aug;13(4):547-557. doi: 10.1007/s11764-019-00774-w. Epub 2019 Jun 27. PubMed PMID: 31250352.
59. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, ... Minoo P, Stewart C, Bathe OF, Gui X, Cohen P, Ramus SJ, Köbel M. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Mod Pathol*. 2019 Jun 25. doi: 10.1038/s41379-019-0302-0. PMID: 31239549.
60. Smith AG, Pereira S, Jaramillo A, Stoll ST, Khan FM, Berka N, Mostafa AA, Pando MJ, Usenko CY, Bettinotti MP, Pyo CW, Nelson WC, Willis A, Askar M, Geraghty DE. Comparison of sequence-specific oligonucleotide probe vs next generation sequencing for HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, and DPB1 typing: Toward single-pass high-resolution HLA typing in support of solid organ and hematopoietic cell transplant programs. *HLA*. 2019 Sep;94(3):296-306. doi: 10.1111/tan.13619. PMID: 31237117.
61. Ho C, Lefresne S, Liberman M, McGuire A, Palma D, Pender A, Snow S, Tremblay A, Myers R. Lung Cancer in Canada. *J Thorac Oncol*. 2019 Jul;14(7):1128-1133. doi: 10.1016/j.jtho.2019.02.012. PubMed PMID: 31235034.



## **Translational and Clinical Research (continued)**

62. Saciragic L, **Nelson G**, Chiarella-Redfern H, Kanarek N, Nation J, **Duggan MA**. Post-colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot RCT. *J Obstet Gynaecol Can.* 2019 Jul;41(7):916-5. doi: 10.1016/j.jogc.2018.08.004. PMID: 31230661.
63. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, ... **Daly A**, ... **Savoie ML**, ... De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Adv.* 2019 Jun 25;3(12):1826-1836. doi: 10.1182/bloodadvances.2019000050. PMID: 31201170; PMCID: PMC6595262.
64. Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, ... **Card C**, et. al. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. *Lung Cancer.* 2019 Jul;133:48-55. PMID: 31200828.
65. Masir N, Akhter A, Roshan TM, Florence CS, Abdul-Rahman F, Tumian NR, Kean-Chang P, Elyamany G, Shabani-Rad MT, **Mansoor A**. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy. *J Clin Pathol.* 2019 Sep;72(9):630-635. doi: 10.1136/jclinpath-2019-205837. PMID: 31189540.
66. **Poon MC**, Shedden N, Card RT. Healthcare professionals in the 'tainted blood' era in Canada: Their forgotten emotions. *Haemophilia.* 2019 Jul;25(4):651-655. doi: 10.1111/hae.13805. Epub 2019 Jun 10. PubMed PMID: 31180617.
67. Abou-Ouf H, Ghosh S, Box A, Palanisamy N, **Bismar TA**. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer. *J Cancer Res Clin Oncol.* 2019 Jul;145(7):1751-1759. doi: 10.1007/s00432-019-02933-z. Epub 2019 May 25. PubMed PMID: 31129769.
68. Kench JG, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, ... **Trpkov K**, et. al. Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. *Virchows Arch.* 2019 Sep;475(3):263-277. PMID: 31098802.
69. Loewen SK, **Doll CM**, Halperin R, Delouya G, Archambault J, Stuckless T, Brundage M. Taking Stock: The Canadian Association of Radiation Oncology 2017 Radiation Oncologist Workforce Study. *Int J Radiat Oncol Biol Phys.* 2019 Sep 1;105(1):42-51. doi: 10.1016/j.ijrobp.2019.04.035. Epub 2019 May 11. PubMed PMID: 31082493.
70. Gareau AJ, Mostafa AA, Stamm L, **Khan F**, Berka N. The identification of a novel HLA-B allele, HLA-B\*27:05:38. *HLA.* 2019 Aug;94(2):157-158. doi: 10.1111/tan.13576.
71. Church DL, **Naugler C**. Benefits and risks of standardization, harmonization and conformity to opinion in clinical laboratories. *Crit Rev Clin Lab Sci.* 2019 Aug;56(5):287-306. doi: 10.1080/10408363.2019.1615408. PMID: 31060412.
72. **Carlson LE**, Subnis UB, Piedalue KL, Vallerand J, Specia M, **Lupichuk S**, **Tang P**, Faris P, Wolever RQ. The ONE-MIND Study: Rationale and protocol for assessing the effects of ONlinE MINDfulness-based cancer recovery for the prevention of fatigue and other common side effects during chemotherapy. *Eur J Cancer Care (Engl).* 2019 Jul;28(4):e13074. doi: 10.1111/ecc.13074. Epub 2019 May 5. PubMed PMID: 31056784.

### **Translational and Clinical Research (continued)**

73. Raphael MJ, Wei X, **Karim S**, Robinson AG, Bedard PL, Booth CM. Neurotoxicity Among Survivors of Testicular Cancer: A Population-based Study. *Clin Oncol (R Coll Radiol)*. 2019 Sep;31(9):653-658. doi: 10.1016/j.clon.2019.04.008. PMID: 31056287.
74. Wijk L, Udumyan R, Pache B, Altman AD, Williams LL, Elias KM, ... **Nelson G**. International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. *Am J Obstet Gynecol*. 2019 Sep;221(3):237.e1-237.e11. doi: 10.1016/j.ajog.2019.04.028. Epub 2019 Apr 30. PubMed PMID: 31051119.
75. Cuvelier GDE, Nemecek ER, Wahlstrom JT, Kitko CL, **Lewis VA**, Schechter T, et. al. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. *Blood*. 2019 Jul 18;134(3):304-316. doi: 10.1182/blood.2019000216.
76. Loewen SK, **Doll CM**, Halperin R, Parliament M, Pearcey RG, Milosevic MF, e. National Trends and Dynamic Responses in the Canadian Radiation Oncology Workforce From 1990 to 2018. *Int J Radiat Oncol Biol Phys*. 2019 Sep 1;105(1):31-41. doi: 10.1016/j.ijrobp.2019.04.019. Epub 2019 Apr 27. PMID: 31039422.
77. Duimering A, Riauka T, Nijjar Y, Ghosh S, MacEwan R, Warkentin H... **Doll C**, Wong C, Joseph K. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. *Radiother Oncol*. 2019 Jul;136:21-28.
78. Glaze S, Duan Q, Sar A, Lee S, **Köbel M**, Park E, **Duggan MA**. FIGO Stage Is the Strongest Prognostic Factor in Adenocarcinoma of the Uterine Cervix. *J Obstet Gynaecol Can*. 2019 Sep;41(9):1318-1324. doi: 10.1016/j.jogc.2019.01.026. PMID: 31006541.
79. **Trpkov K**, Bonert M, Gao Y, Kapoor A, He H, Yilmaz A, et. al. High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. *Histopathology*. 2019 Sep;75(3):440-442. doi: 10.1111/his.13876. Epub 2019 Jul 2. PMID: 31002177.
80. Macones GA, Caughey AB, Wood SL, Wrench IJ, Huang J, Norman M, Pettersson K, Fawcett WJ, Shalabi MM, Metcalfe A, Gramlich L, **Nelson G**, Wilson RD. Guidelines for postoperative care in cesarean delivery: Enhanced Recovery After Surgery (ERAS) Society recommendations (part 3). *Am J Obstet Gynecol*. 2019 Sep;221(3):247.e1-247.e9. doi: 10.1016/j.ajog.2019.04.012. Epub 2019 Apr 14. PubMed PMID: 30995461.
81. Kennedy ED, Simunovic M, Jhaveri K, Kirsch R, Brierley J, Drolet S, ... **MacLean T**, et. al. Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial. *JAMA Oncol*. 2019 Jul 1;5(7):961-966.
82. Sanders S, Chua N, Larouche JF, **Owen C**, **Shafey M**, **Stewart DA**. Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepea-Busulfan Conditioning for Transplantation-Eligible Patients. *Biol Blood Marrow Transplant*. 2019 Aug;25(8):1505-1510. doi: 10.1016/j.bbmt.2019.04.004. PMID: 30965138.
83. Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, ... **Husain SM**, et. al. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. *Int J Radiat Oncol Biol Phys*. 2019 Aug 1;104(5):1057-1065. doi: 10.1016/j.ijrobp.2019.03.049. PMID: 30959123; PubMed Central PMCID: PMC6646073.

### **Translational and Clinical Research (continued)**

84. **Trpkov K**, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR, Yilmaz A, Wang C, San Miguel Fraile P, Perez Montiel DM, Bulimbasić S, Rogala J, Hes O. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? *Histopathology*. 2019 Aug;75(2):174-184. doi: 10.1111/his.13865. PMID: 30895640.
85. Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, **Balogh A**, et. al. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. *Int J Radiat Oncol Biol Phys*. 2019 Jul 1;104(3):522-529. doi: 10.1016/j.ijrobp.2019.03.004. PMID: 30858143.
86. Gill P, Howell J, **Naugler C**, Daoud MSA. Utility of Multistep Protocols in the Analysis of Sentinel Lymph Nodes in Cutaneous Melanoma: An Assessment of 194 Cases. *Arch Pathol Lab Med*. 2019 Sep;143(9):1126-30. doi: 10.5858/arpa.2018-0316-OA. PMID: 30855172.
87. Prokopishyn NL, Logan BR, Kiefer DM, Sees JA, Chitphakdithai P, Ahmed IA, ... **Daly A**, ... Pulsipher MA, Shah NN, Switzer GE, O'Donnell PV, Confer DL, Shaw BE. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. *Biol Blood Marrow Transplant*. 2019 Jul;25(7):1325-1330. doi: 10.1016/j.bbmt.2019.01.034. PMID: 30716454; PubMed Central PMCID: PMC6615955.
88. Velde NV, **Demetrick DJ**, Duignan PJ. Primary Pleural Squamous Cell Carcinoma in a Free-Ranging River Otter (*Lontra canadensis*). *J Wildl Dis*. 2019 Jul;55(3):728-732. doi: 10.7589/2018-07-181. Epub 2019 Jan 31. PubMed PMID: 30702954.
89. Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, **Stewart DA**, et. al. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. *Leuk Lymphoma*. 2019 Aug;60(8):1934-1941. doi: 10.1080/10428194.2018.1563691. PMID: 30628511; PMCID: PMC6620162.
90. Ustun C, Young JH, Papanicolaou GA, Kim S, Ahn KW, Chen M, ... **Daly A**, et. al. Bacterial blood stream infections, particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2019 Aug; 54(8):1254-65. doi: 10.1038/s41409-018-0401-4. PMID: 30546070.
91. Kim HL, Li P, Huang HC, Dehesi S, Marti T, Knudsen B, ... **Hyndman ME**, **Bismar TA**. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. *Prostate Cancer Prostatic Dis*. 2019 Sep;22(3):399-405. doi: 10.1038/s41391-018-0101-6. Epub 2018 Dec 12. PubMed PMID: 30542054.
92. Tarr GAM, Chui L, Lee BE, Pang XL, Ali S, Nettel-Aguirre A, ... **Dickinson J**, Tarr PI, Drews S, MacDonald J, Kim K, Freedman SB. Performance of Stool-testing Recommendations for Acute Gastroenteritis When Used to Identify Children With 9 Potential Bacterial Enteropathogens. *Clin Infect Dis*. 2019 Sep 13;69(7):1173-82. doi: 10.1093/cid/ciy1021.
93. Gillis C, Martin L, Gill M, Gilmour L, **Nelson G**, Gramlich L. Food Is Medicine: A Qualitative Analysis of Patient and Institutional Barriers to Successful Surgical Nutrition Practices in an Enhanced Recovery After Surgery Setting. *Nutr Clin Pract*. 2019 Aug;34(4):606-615. doi: 10.1002/ncp.10215. Epub 2018 Nov 14. PubMed PMID: 30430630.
94. Gill P, **Naugler C**, Abi Daoud MS. Utility of Ber-EP4 and MOC-31 in Basaloid Skin Tumor Detection. *Appl Immunohistochem Mol Morphol*. 2019 Sep;27(8):584-588. doi: 10.1097/PAI.0000000000000664. PubMed PMID: 29629953.



**Arnie Charbonneau  
Cancer Institute**



## **Arnie Charbonneau Cancer Institute**

Health Research Innovation Centre

3280 Hospital Drive NW

Calgary, Alberta T2N 4Z6

T 1.403.210-3934

E [charbonneau@ucalgary.ca](mailto:charbonneau@ucalgary.ca)

[charbonneau.ucalgary.ca](http://charbonneau.ucalgary.ca)